Quilostigmine
Acetylcholinesterase inhibitor
From Wikipedia, the free encyclopedia
Quilostigmine, also known as NXX-066, is an acetylcholinesterase inhibitor. Its structure is related to that of physostigmine,[1] another acetylcholinesterase (AChE) inhibitor.
| Names | |
|---|---|
| IUPAC name
[(3aR,8bS)-3,4,8b-Trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] 3,4-dihydro-1H-isoquinoline-2-carboxylate | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C23H27N3O2 | |
| Molar mass | 377.488 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Biological activity
History
Quilostigmine was initially studied by AstraZeneca for the treatment of Alzheimer's disease;[3][4] however, the drug appears to have been discontinued,[5] reaching a maximum trial phase of two.[6]
